RCAP
ORKA

Resolute Capital Asset Partners’s Oruka Therapeutics ORKA Stock Holding History

Resolute Capital Asset Partners’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$613K Hold
12,500
– – 0.32% 39
2025
Q4 		$379K Sell
12,500
-62,500
-83% -$1.74M 0.18% 46
2025
Q3 		$1.44M Buy
+75,000
New +$1.11M 0.75% 39

Other funds holding ORKA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Resolute Capital Asset Partners's ORKA Position: Q1 2026 in Review

Resolute Capital Asset Partners held its Oruka Therapeutics (ORKA) position steady in Q1 2026 at 12,500 shares worth $613K. The position accounts for 0.32% of the portfolio, ranked #39.

Resolute Capital Asset Partners first reported a position in ORKA in Q3 2025 and has held it in 3 quarters since. The position peaked at $1.44M in Q3 2025. 184 funds tracked by Wall St. Rank hold ORKA as of Q1 2026.

  • Resolute Capital Asset Partners held 12,500 shares of Oruka Therapeutics worth $613K as of Q1 2026.
  • Resolute Capital Asset Partners left its Oruka Therapeutics share count unchanged in Q1 2026.
  • Oruka Therapeutics made up 0.32% of Resolute Capital Asset Partners's portfolio in Q1 2026, its #39 holding.
  • Resolute Capital Asset Partners first reported a position in Oruka Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Resolute Capital Asset Partners's Oruka Therapeutics position peaked at $1.44M in Q3 2025.
  • 184 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q1 2026.

Based on Resolute Capital Asset Partners's 13F filing for Q1 2026, filed 15 May 2026.